Sareum Holdings PLC - Global Licensing of FL3+Aurora Programme
Sareum Signs Global Licensing Deal for its FLT3+Aurora Kinase Inhibitor Programme with a
Under the terms of the Agreement, the Licensee has been granted an exclusive worldwide licence to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including
The Licensee is principally engaged in research and development, production and sales of innovative drugs, including oncology drugs, in
Under the terms of the Agreement, the Licensee will fund all future development activities in relation to the Compounds and has been granted sole rights to market any resulting products worldwide.
Under the Agreement,
Since all research and development expenditure is written off as it occurs, in line with standard industry practise, the Compounds covered by the Agreement are held at nil value on
"With this programme now partnered, we are wholly focused on advancing the development of our proprietary TYK2/JAK1 inhibitors through preclinical studies and look forward to providing updates as material milestones are reached."
This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014
For further information, please contact:
James Dance / Richard Tulloch 020 7409 3494
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow/ David Dible 020 7638 9571
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting completion of preclinical development for each molecule in 2020.
The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
SRA737 was discovered and initially developed by scientists at
- Ends -
This information is provided by RNS, the news service of the
Quick facts: Sareum Holdings PLC
Market Cap: £17.35 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE